Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent, University of Rouen and A*STAR’s Bioprocessing Technology Institute to Collaborate

Published: Thursday, May 23, 2013
Last Updated: Thursday, May 23, 2013
Bookmark and Share
The collaborations aims to further innovation in biopharmaceuticals and glycomics through developing tools to effectively analyze biologics and vaccines.

Biologics are molecules such as antibodies and other recombinant protein-based therapeutics. Used in combination with vaccines, they can prevent or treat a variety of serious medical conditions such as cancers, immune disorders and infectious diseases that affect millions of people annually. These therapeutic agents are typically produced by bioprocesses using living cells as factories for their production. 

Unlike small molecule drugs, biologics produced by cells are typically more heterogeneous in structure, most notably in glycosylation, which is the modification of protein drugs by sugars (also known as glycans). Sugars are known to prolong the half-life of biologic drugs and thereby reduce the frequency and dosage of drugs given to human patients.

A*STAR’s Bioprocessing Technology Institute will join forces with the University of Rouen’s Glyco-MEV laboratory and Agilent to develop innovative analytical techniques to ensure that these biologics are safe and effective. BTI is currently working to develop methods of producing and analyzing these biologics in animal cells while Glyco-MEV laboratory specializes in the production of those molecules in plant systems.

This strategic partnership strengthens the collaboration between BTI and Glyco-MEV laboratory and is enhanced by Agilent’s technological expertise to develop new, sensitive and high-throughput methodologies that are particularly adapted to the analysis of biopharmaceuticals. In addition, the Glyco-MEV laboratory will be Agilent’s glycomics reference site in Europe, and BTI will be its glycomics reference site for Southeast Asia. 

Professor Lam Kong Peng, executive director of BTI, said, “With increasing use of biologics to treat human diseases and with more biosimilars coming to market in the next few years, it is timely for BTI to develop novel technologies that would improve the characterization and analysis of protein-based drugs. This collaboration would enhance Singapore’s reputation as a world-class destination for biologics manufacturing and R&D.”

“This collaboration will enhance our international expertise with regards to the glycan analysis and engineering of biopharmaceuticals produced in plant and microalgae cells,” said Prof Patrice Lerouge, director of the Glyco-MEV laboratory. “We also hope that such a research initiative will facilitate exchanges of lab members and PhD students between Singapore and France.”

“This research initiative enables scientists to optimize glycan analytical workflows on the Agilent HPLC-Chip/MS system,” said Dr. Rudolf Grimm, Agilent’s director of science and technology and manager of collaborations in the Asia-Pacific region. “We look forward to working with these leading organizations to drive discovery in this important field.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Technologies to Build New Facility in Colorado
Agilent buys 20 acres in Weld County to increase pharmaceutical manufacturing capacity.
Wednesday, August 10, 2016
Agilent Extends Agreement with PerkinElmer on Bioanalyzer Chips
PerkinElmer supplies chips for Agilent's popular 2100 Bioanalyzer system.
Thursday, January 21, 2016
Agilent, Singapore Institute Collaborate
Agilent Technologies and Singapore's Bioprocessing Technology Institute today announced a collaboration to develop new analytical approaches to specific protein-linked sugar compounds.
Wednesday, July 15, 2015
Agilent Collaborate with A*STAR’s Bioprocessing Technology Institute
Collaboration addresses a critical need in the biopharmaceutical industry.
Tuesday, July 14, 2015
Utilizing Fast HPLC Screening Methods for the Detection of Steroids
Analysis of steroids improved by choosing the optimal HPLC column for the separation.
Saturday, January 17, 2015
How to Achieve High-Speed, High-Resolution Glycan Mapping for mAb Characterization
The full characterization of biotherapeutics is required by regulatory authorities as properties such as safety, efficacy and the serum half-life of therapeutic proteins can be affected by differences in their glycosylation pattern.
Monday, December 22, 2014
Agilent Supports Inaugural Singapore-South Korea Symposium on Glycomics
Event follows collaboration to develop tools for analysis of biologics, vaccines.
Saturday, February 15, 2014
Agilent Announces Agreement with Picometrics Technologies
Agilent to provide Picometrics' biopharmaceutical customers with combined solutions for capillary electrophoresis (CE), laser induced fluorescence (LIF) detection and mass spectrometry.
Friday, January 17, 2014
Agilent Technologies, University of Rouen and A*STAR’s Bioprocessing Technology Institute Collaborate
Organisations will work together to further innovation in biopharmaceuticals and glycomics.
Thursday, May 23, 2013
Agilent Technologies Introduces Verified Dissolution Components for Pharmaceutical Market
Agilent Technologies Inc. introduced a new series of verified dissolution components, including molded vessels as well as paddle and basket shafts.
Wednesday, May 15, 2013
Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer
Dako receives clearance to sell FLEX Monoclonal Rabbit Anti-Human Estrogen Receptor a, Clone EP1 in US.
Monday, April 08, 2013
Agilent Technologies and Chungnam National University Announce Glycomics Research Initiatives
The collaboration hopes to develop biomarkers and new therapeutic antibodies to combat diseases such as cancer.
Tuesday, April 02, 2013
Merck-Serono Adopts Agilent Technologies’ Electronic Lab Notebook for Biology Research
Agilent Technologies Inc. have announced that Merck-Serono, a division of Merck KGaA, Darmstadt, Germany, has selected the Agilent OpenLAB Electronic Lab Notebook (ELN) to enhance scientific collaboration globally throughout R&D for finding new small molecules and biopharmaceuticals.
Tuesday, November 23, 2010
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Developing a Vaccine for Sexually Transmitted and Insect-Borne Zika Infections
Prokarium announce the beginning of a programme to develop an oral vaccine against Zika infection.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!